Timing of Pharmacological Treatment for Patent Ductus Arteriosus and Risk of Secondary Surgery, Death or Bronchopulmonary Dysplasia: A Population-Based Cohort Study of Extremely Preterm Infants

Publisher： Karger

E-ISSN： 1661-7819|107|2|87-92

ISSN： 1661-7800

Source： Neonatology, Vol.107, Iss.2, 2014-11, pp. : 87-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes

By  

Neonatology, Vol. 111, Iss. 4, 2017-01 ,pp. : 367-375

Karger

Access to resources Recommend Favorite

The Importance of Echocardiography and an Individual Approach to Patent Ductus Arteriosus Treatment in Extremely Preterm Infants

By  

Neonatology, Vol. 107, Iss. 4, 2015-02 ,pp. : 257-257

Karger

Access to resources Recommend Favorite

Future Benefits of Sequential Echocardiography: Unmasking the Indications for Treatment of Patent Ductus Arteriosus in Extremely Preterm Infants

By  

Neonatology, Vol. 108, Iss. 2, 2015-06 ,pp. : 99-99

Karger

Access to resources Recommend Favorite

Minimal Effective Dose of Indomethacin for the Treatment of Patent Ductus arteriosus in Preterm Infants

By  

Neonatology, Vol. 81, Iss. 2, 2002-02 ,pp. : 91-94

Karger

Access to resources Recommend Favorite

An Elevation of Serum Ferritin Level Might Increase Clinical Risk for the Persistence of Patent Ductus Arteriosus, Sepsis and Bronchopulmonary Dysplasia in Erythropoietin-Treated Very-Low-Birth-Weight Infants

By  

Neonatology, Vol. 111, Iss. 1, 2016-08 ,pp. : 68-75

Karger

Access to resources Recommend Favorite